BRAF and serous adenocarcinoma: TP53 mutations (≥50%), and, to a lesser extent, possibly HER2/neu and AKT2 gene amplifications, are genetic alterations that are associated with high-grade serous carcinomas, whereas BRAF and KRAS mutations are found in two-thirds of low-grade serous carcinomas [64].